Table 3.
The rate of treatment-related adverse events of the study cohort
| Adverse event | Frequency [cases (%)] | |||
|---|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | Grade 4 | |
| Hematologic | ||||
| Neutropenia | 20 (30.8) | 15 (23.1) | 4 (6.2) | 4 (6.2) |
| Thrombocytopenia | 9 (13.8) | 2 (3.1) | 0 | 0 |
| Anemia | 24 (36.9) | 3 (4.6) | 0 | 1 (1.5) |
| Nonhematologic | ||||
| Loss of appetite | 34 (52.3) | 18 (27.7) | 0 | 0 |
| Nausea | 26 (40.0) | 18 (27.7) | 0 | 0 |
| Vomiting | 14 (21.5) | 19 (29.2) | 1 (1.5) | 0 |
| Mucosal inflammation | 14 (21.5) | 1 (1.5) | 0 | 0 |
| Diarrhea | 20 (30.8) | 4 (6.2) | 4 (6.2) | 0 |
| Alopecia | 52 (80.0) | 13 (20.0) | – | – |
| Fatigue | 25 (38.5) | 10 (15.4) | 0 | 0 |
| Sensory neuropathy | 18 (27.7) | 3 (4.6) | 0 | 0 |
| Weight loss | 7 (10.8) | 0 | 0 | 0 |
| Constipation | 7 (10.8) | 1 (1.5) | 0 | 0 |
| Alanine aminotransferase elevation | 22 (33.8) | 7 (10.8) | 1 (1.5) | 0 |
| Aspartate aminotransferase elevation | 12 (18.5) | 4 (6.2) | 0 | 0 |
| Bilirubin elevation | 4 (6.2) | 0 | 0 | 0 |
| Allergic reaction | 1 (1.5) | 0 | 0 | 0 |
| Rash | 1 (1.5) | 0 | 0 | 0 |
| Hand-foot syndrome | 1 (1.5) | 0 | 0 | 0 |
| Singultus | 1 (1.5) | 0 | 0 | 0 |